CHOOLIP & SCIENCES Inc
Aptamer biotech developing ApDC drug candidates AST-201 and AST-202 for solid and blood cancers, plus a bioanalytical CRO business.
As of 2026-10-10, CHOOLIP & SCIENCES Inc has 4 Korean MFDS device approvals on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureChoolip & Sciences Inc was spun off from POSTECH in April 2011 and listed on KOSDAQ in September 2020 as an aptamer technology platform biotech. Using its aptamer-drug conjugate (ApDC®) platform, it develops solid-tumor drug candidate AST-201 and blood-cancer candidate AST-202, alongside the aptamer-based lung cancer risk test AptoDetect™-Lung. Through an August 2024 merger it entered the CRO business analyzing antibody drugs, ADCs, and peptides, states it shortened typical 5-7 year drug candidate discovery to about 3 years, and is running a Phase 1 trial of AST-201 at four hospitals in Korea.
Products & technology
- AST-201Solid tumor (GPC3-positive) therapeutic candidate for HCC and NSCLC
- AST-202Blood cancer (CD25-positive) therapeutic candidate for TCL and AML
- AptoDetect™-LungBlood protein biomarker and algorithm-based lung cancer risk test
Regulatory approvals
data.go.kr4 Korean MFDS device approvals · 2015–2024
- MFDSIVD reagents for tumor marker2024-03-18Product approval · Class 3체외 제허 24-197 호
- MFDSIVD reagents for tumor marker2023-01-09Product approval · Class 3체외 제허 23-13 호
- MFDSIVD reagents for tumor marker2017-09-26Product approval · Class 3체외 제허 17-748 호
- MFDSIVD reagents for tumor markerRevoked2015-07-09Product approval · Class 3체외 제허 15-1125 호
R&D and key agreements
Source: DART corporate disclosureAST-201 · 고형암(GPC3-양성) · 임상 1a/b상 진행 중(국내 4개 병원) · Cohorts 1-4 showed good tolerability with no dose-limiting toxicity; Cohort 5 (16 mg/kg) dosing ongoing as of Dec 2025
AST-202 · 혈액암(CD25-양성) · 전임상 연구 단계 · In vitro metabolic stability and rat PK analysis completed; efficacy evaluation ongoing in resistant/refractory AML in vitro model
AST-203a · 고형암(Trop2-양성), 췌장암·폐암·유방암 · 후보물질 발굴 및 전임상 연구 단계(선도물질 최적화) · Efficacy evaluation ongoing in pancreatic cancer orthotopic mouse model
Key disclosures
KRX KIND via OpenDARTShow 8 more events
Patents
KIPRIS · applicant-matchedPublished · 2023-12 · Application 1020230191732
Published · 2023-11 · Application 1020230149904
Rejected · 2023-03 · Application 1020230031194
Withdrawn · 2022-03 · Application 1020220034081
Withdrawn · 2022-03 · Application 1020220027495
Withdrawn · 2021-06 · Application 1020210082374
Rejected · 2021-04 · Application 1020210052645
Registered · 2019-11 · Application 1020190142363
Registered · 2019-02 · Application 1020190013775
Registered · 2018-08 · Application 1020207006933
Show 4 more patents
Registered · 2017-04 · Application 1020170053294
Registered · 2015-09 · Application 1020187007151
Registered · 2015-09 · Application 1020207004010
Expired · 2015-05 · Application 1020150066489
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot50
- GoogleGoogleOther2
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
Measured since Aug 25, 2026 · 4 AI engines · last read Oct 8, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for CHOOLIP & SCIENCES Inc and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.
Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
KOSDAQ-listed bioprocess and biomedical company supplying the CELBIC single-use cell culture system and the DxBIC automated analysis system.
Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.
Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition